Published in Support Care Cancer on November 10, 2012
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 1.93
Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial. Lancet Oncol (2015) 1.41
Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model. PLoS One (2015) 1.41
Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.04
Radiation enteropathy--pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol (2014) 1.02
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
Herbal medicines for the treatment of cancer chemotherapy-induced side effects. Front Pharmacol (2015) 0.94
A traditional Japanese medicine--Hangeshashinto (TJ-14)--alleviates chemoradiation-induced mucositis and improves rates of treatment completion. Support Care Cancer (2014) 0.93
Radiation-induced small bowel disease: latest developments and clinical guidance. Ther Adv Chronic Dis (2014) 0.90
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. World J Gastroenterol (2014) 0.88
Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice. Br J Pharmacol (2014) 0.88
Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. BMJ Support Palliat Care (2015) 0.85
Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 0.83
Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis. Support Care Cancer (2015) 0.83
Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care (2015) 0.79
The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis. PLoS One (2015) 0.79
Prevention of pelvic radiation disease. World J Gastrointest Pharmacol Ther (2015) 0.79
Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer. Prostate Cancer (2015) 0.78
The MASCC/ISOO mucositis guidelines: dissemination and clinical impact. Support Care Cancer (2013) 0.78
A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer (2014) 0.78
Efficacy and safety of transdermal fentanyl for the treatment of oral mucositis pain caused by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Support Care Cancer (2014) 0.78
Combined Effects of Muricid Extract and 5-Fluorouracil on Intestinal Toxicity in Rats. Evid Based Complement Alternat Med (2015) 0.78
Complementary strategies for the management of radiation therapy side effects. J Adv Pract Oncol (2013) 0.77
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Mol Cancer (2014) 0.77
Efficacy of elemental diet on prevention for chemoradiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma. Support Care Cancer (2015) 0.77
Effect of inulin and fructo-oligosaccharide on the prevention of acute radiation enteritis in patients with gynecological cancer and impact on quality-of-life: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr (2015) 0.75
A Randomized, Double-Blind Pilot Trial of Hydrolyzed Rice Bran versus Placebo for Radioprotective Effect on Acute Gastroenteritis Secondary to Chemoradiotherapy in Patients with Cervical Cancer. Evid Based Complement Alternat Med (2015) 0.75
Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res (2017) 0.75
Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials (2017) 0.75
Properdin deficiency protects from 5-fluorouracil induced small intestinal mucositis in a complement activation independent, IL-10 dependent mechanism. Clin Exp Immunol (2017) 0.75
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. Target Oncol (2016) 0.75
Prophylactic and therapeutic effects of oral budesonide for acute radiation-induced enteritis and colitis in rats. Int J Clin Exp Med (2014) 0.75
Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa. PLoS One (2017) 0.75
Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol (1996) 6.51
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 3.83
Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer (2007) 2.95
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol (2006) 2.59
The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer (2003) 2.46
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer (2004) 2.29
Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet (2000) 2.09
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol (2005) 1.98
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys (2001) 1.72
Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol (1998) 1.70
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut (2001) 1.61
Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys (2007) 1.61
Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood (1997) 1.61
Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplant (2002) 1.53
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol (2003) 1.51
Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys (1996) 1.50
Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol (2001) 1.44
Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN J Parenter Enteral Nutr (2009) 1.42
The safety of probiotics. Clin Infect Dis (2008) 1.40
Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci (1991) 1.36
A randomized trial on the effect of a multimodal intervention on physical capacity, functional performance and quality of life in adult patients undergoing allogeneic SCT. Bone Marrow Transplant (2009) 1.20
Treatment of radiation proctitis with hyperbaric oxygen. Radiother Oncol (2005) 1.18
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res (2001) 1.17
Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer (2006) 1.16
Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys (2002) 1.15
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer (2007) 1.13
Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys (2008) 1.13
Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol (2007) 1.10
Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys (2007) 1.08
Metronidazole in the treatment of chronic radiation proctitis: clinical trial. Croat Med J (2000) 1.06
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 1.05
Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol (2010) 1.03
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist (2006) 1.03
Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol (2006) 1.03
Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol (2002) 1.02
The efficacy of hyperbaric oxygen therapy in the treatment of radiation-induced late side effects. Int J Radiat Oncol Biol Phys (2004) 1.02
A randomized prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia. Gastrointest Endosc (1997) 0.99
Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol (2003) 0.98
Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. J Clin Oncol (2000) 0.97
Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. Dig Dis Sci (1999) 0.96
Reversibility of lower reproductive tract abnormalities in women with Schistosoma haematobium infection after treatment with praziquantel--an interim report. Acta Trop (1996) 0.95
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol (2006) 0.94
High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol (1999) 0.94
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. Int J Radiat Oncol Biol Phys (2005) 0.93
Gastrointestinal mucositis: a new biological model. Support Care Cancer (2003) 0.92
A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. Am J Gastroenterol (2000) 0.92
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol (2004) 0.91
A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol (1997) 0.91
Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol (1993) 0.91
Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs (1993) 0.91
Prevention of radiochemotherapy-induced esophagitis with glutamine: results of a pilot study. Int J Radiat Oncol Biol Phys (2007) 0.90
Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer (2001) 0.89
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemother Pharmacol (2005) 0.88
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer (2004) 0.88
Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer (2002) 0.88
Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. J Int Med Res (2008) 0.88
Hyperbaric oxygen--an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol (2001) 0.88
Pharmacotherapy for chronic hemorrhagic radiation proctitis. World J Surg (2002) 0.87
Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. Int J Radiat Oncol Biol Phys (2006) 0.87
Hyperbaric oxygen treatment of hemorrhagic radiation-induced gastritis after esophagectomy. Ann Thorac Surg (2005) 0.86
The treatment of stage 3 carcinoma of the cervix by external radiotherapy and high-pressure oxygen. Br J Radiol (1969) 0.86
Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. Strahlenther Onkol (2003) 0.86
Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study. Strahlenther Onkol (2009) 0.85
The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: a double-blind, randomized trial. Int J Radiat Oncol Biol Phys (2001) 0.85
Severe hemorrhagic radiation proctitis advancing to gradual cessation with hyperbaric oxygen. Dig Dis Sci (1991) 0.85
A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Support Care Cancer (2005) 0.85
Circadian rhythms in the incidence of apoptotic cells and number of clonogenic cells in intestinal crypts after radiation using normal and reversed light conditions. Int J Radiat Biol Relat Stud Phys Chem Med (1988) 0.84
Efficacy of prophylactic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer. Anticancer Res (2003) 0.84
A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol (R Coll Radiol) (1993) 0.84
Hyperbaric oxygen treatment for radiation proctitis. Int J Radiat Oncol Biol Phys (1997) 0.84
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol (1999) 0.84
Gut protection by palifermin during autologous haematopoietic SCT. Bone Marrow Transplant (2008) 0.84
The effect of a multidimensional exercise programme on symptoms and side-effects in cancer patients undergoing chemotherapy--the use of semi-structured diaries. Eur J Oncol Nurs (2006) 0.83
Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma. Cancer (2010) 0.83
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 0.83
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 0.83
A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. Int J Radiat Oncol Biol Phys (2002) 0.83
A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol (1997) 0.83
Activated charcoal to prevent irinotecan-induced diarrhea in children. Pediatr Blood Cancer (2008) 0.83
Treatment of refractory radiation-induced hemorrhagic proctitis with hyperbaric oxygen therapy. Am J Clin Oncol (2006) 0.83
Hyperbaric oxygen therapy for delayed radiation injuries in gynecological cancers. Int J Gynecol Cancer (2006) 0.82
Hyperbaric oxygen as a treatment for malabsorption in a radiation-damaged short bowel. Eur J Gastroenterol Hepatol (2006) 0.82
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. Cancer Chemother Pharmacol (2006) 0.82
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol (2002) 0.82
Control of radiation-induced diarrhea with cholestyramine. Int J Radiat Oncol Biol Phys (1979) 0.82
Formalin instillation for hemorrhagic radiation proctitis. Surg Innov (2005) 0.82
Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. Radiother Oncol (2000) 0.82
Improved quality of life with hyperbaric oxygen therapy in patients with persistent pelvic radiation-induced toxicity. Clin Oncol (R Coll Radiol) (2008) 0.81
Prophylaxis of diarrhoea in patients submitted to radiotherapeutic treatment on pelvic district: personal experience. Dig Liver Dis (2002) 0.81
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol (2004) 0.81
Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol (2001) 0.81
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Invest New Drugs (2006) 0.81
Nutritional symptom and body composition outcomes of aerobic exercise in women with breast cancer. Clin Nurs Res (2010) 0.81
Effect of ethanol on fatal carbon monoxide poisoning in awake mice [correction of rats]. Toxicol Lett (1990) 0.81
Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies. Support Care Cancer (2004) 0.81
Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis (2009) 2.49
Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol (2007) 2.24
Animal models of mucositis: implications for therapy. J Support Oncol (2011) 2.13
Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol (2012) 2.07
Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab (2006) 1.98
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer (2014) 1.93
Effect of stressful life events on the onset and duration of recurrent aphthous stomatitis. J Oral Pathol Med (2011) 1.66
Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer (2006) 1.64
Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.58
Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum (2011) 1.54
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev (2007) 1.47
A survey of the current approaches to diagnosis and management of oral premalignant lesions. J Am Dent Assoc (2007) 1.47
Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 1.46
Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. Haematologica (2005) 1.40
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU). Cancer Biol Ther (2009) 1.39
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother (2011) 1.39
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol (2007) 1.35
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant (2010) 1.33
Management of dental patients taking common hemostasis-altering medications. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 1.31
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg (2009) 1.26
Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.23
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 1.17
Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.16
Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer (2006) 1.16
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol (2008) 1.12
Interruption of warfarin anticoagulation for dental surgery. Chest (2013) 1.11
Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer (2006) 1.10
Oral mucositis. Oral Oncol (2010) 1.10
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) (2009) 1.07
Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol (2006) 1.07
Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther (2008) 1.06
Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig (2010) 1.06
Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther (2008) 1.05
Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol (2003) 1.05
Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol (2010) 1.05
Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.04
Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer (2012) 1.03
Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.02
Reduced dietary intake of vitamin B12 and folate in patients with recurrent aphthous stomatitis. J Oral Pathol Med (2010) 1.01
Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer (2005) 1.01
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer (2009) 1.01
Irinotecan-induced mucositis is associated with changes in intestinal mucins. Cancer Chemother Pharmacol (2008) 1.00
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer (2013) 1.00
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.99
Oropharyngeal candidiasis in head and neck cancer patients treated with radiation: update 2011. Support Care Cancer (2011) 0.99
The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis (2011) 0.99
Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci (2002) 0.99
Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol (2013) 0.98
Emerging evidence on the pathobiology of mucositis. Support Care Cancer (2013) 0.97
A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis, p53, nuclear factor-kappaB, COX-1, and COX-2. Mol Cancer Ther (2007) 0.96
Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer (2012) 0.96
Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract (2012) 0.95
Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. Cancer Biol Ther (2009) 0.94